UNIVERSITY OF ARKANSAS SYSTEM
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1871-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.web.uams.edu
Clinical Trials
56
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Comparison Between a Live Canine or Toy Dog on Prosocial Behavior and Emotional Regulation in Autistic Children
- Conditions
- Prosocial BehaviorEmotional RegulationHuman Animal BondingHuman Animal InteractionAutism
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- University of Arkansas, Fayetteville
- Target Recruit Count
- 9
- Registration Number
- NCT06915415
- Locations
- 🇺🇸
University of Arkansas, Fayetteville, Arkansas, United States
Protein and Exercise for Postmenopausal Women's Wellbeing
- Conditions
- Postmenopausal
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- University of Arkansas, Fayetteville
- Target Recruit Count
- 90
- Registration Number
- NCT06849817
- Locations
- 🇺🇸
Don tyson Center for Agricultural Sciencers, Fayetteville, Arkansas, United States
🇺🇸University of Arkansas, Fayetteville, Arkansas, United States
Animal-Assisted Therapy in Pediatric Autism Spectrum Disorders
- Conditions
- Pediatric AutismDevelopmental Delay (Disorder)Behavioral Concerns
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of Arkansas, Fayetteville
- Target Recruit Count
- 13
- Registration Number
- NCT06687850
- Locations
- 🇺🇸
University of Arkansas, Fayetteville, Arkansas, United States
Targeting Components of Distress Tolerance
- Conditions
- Distress, Emotional
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- University of Arkansas, Fayetteville
- Target Recruit Count
- 240
- Registration Number
- NCT06570603
- Locations
- 🇺🇸
University of Arkansas - Fayetteville, Fayetteville, Arkansas, United States
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- University of Arkansas, Fayetteville
- Target Recruit Count
- 30
- Registration Number
- NCT06115603
- Locations
- 🇺🇸
University of Arkansas, Fayetteville, Arkansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Breakthrough at UT Health San Antonio: Chemical Endocytic Strategy Could Transform IV Drugs into Oral Treatments
• Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously. • The discovery leverages CD36 protein receptors on cell surfaces to facilitate cellular uptake of large and water-soluble drugs, potentially overcoming the blood-brain barrier for treating conditions like brain cancer and Alzheimer's disease. • This paradigm shift in drug delivery could revolutionize pharmaceutical development, resurrect previously abandoned drug candidates, and enable more personalized medicine based on patients' varying CD36 expression levels.
UAMS Awarded $2.2 Million Grant to Investigate Efferocytosis in Retinopathy
The University of Arkansas for Medical Sciences (UAMS) has received a $2.2 million grant from the National Eye Institute (NEI).
Real-World Teclistamab Data Shows Comparable Efficacy to Clinical Trials Despite Higher Toxicity Rates in Multiple Myeloma
A multicenter real-world study of 110 patients treated with teclistamab demonstrated a 62% overall response rate and 51% very good partial response rate, comparable to the pivotal MajesTEC-1 trial despite treating a more heavily pretreated population.